CJC-1295 vs GHRP-6: mechanism, evidence, and dosing differences

Last updated 2026-07-26

What are CJC-1295 and GHRP-6, and how are they different?

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), engineered from the first 29 amino acids of native GHRH with substitutions that resist enzymatic breakdown ^[1]. It binds the GHRH receptor on pituitary somatotrophs and tells the pituitary to release growth hormone in a pulse that mimics the body's own rhythm. GHRP-6 is different. It's a growth hormone releasing peptide, one of the original hexapeptides developed in the 1980s alongside GHRP-2. It's a ghrelin-receptor agonist (GHS-R1a), meaning it works through the same receptor that the hunger hormone ghrelin uses ^[2]. That shared pathway is why GHRP-6 is notorious for making people ravenous within 20 to 30 minutes of a dose. The core distinction: CJC-1295 amplifies a GH pulse through the GHRH receptor, GHRP-6 triggers a GH pulse through the ghrelin receptor and also suppresses somatostatin, the hormone that normally puts the brakes on GH release ^[3]. Different locks, different keys, same downstream hormone. Neither compound is FDA-approved for human use. Both are sold as research chemicals, and the FDA has published guidance stating that CJC-1295 and similar peptides don't meet the criteria for compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act ^[4]. For background on the molecule's origin and study history, see cjc 1295.

How do their mechanisms of action actually compare?

CJC-1295 works upstream of GH release by binding the GHRH receptor, activating adenylate cyclase, and raising cyclic AMP inside the somatotroph cell. This increases both the number of somatotrophs that fire and the amount of GH each one releases per pulse. It does not touch ghrelin receptors and has no meaningful direct effect on appetite. GHRP-6 works through GHS-R1a, the same receptor ghrelin activates in the pituitary and the hypothalamus. Activating this receptor does two things at once: it stimulates GH release somewhat independently of GHRH signaling, and it activates hypothalamic neurons that drive hunger. That second effect is not a side effect in the pharmacological sense, it's the primary action of the receptor. GH release is almost a bonus. Because the two compounds converge on GH release through non-overlapping receptors, combining them theoretically produces a larger GH pulse than either alone. Early clinical pharmacology work on combining a GHRH analogue with a GHRP found a greater-than-additive GH release compared to either agent alone ^[5]. That data comes from short-term studies using different GHRP compounds and GHRH analogues than the specific commercial versions sold today, so it supports the mechanistic logic more than it validates any particular product combination people buy online. | Feature | CJC-1295 | GHRP-6 |

What does DAC mean, and does GHRP-6 have a DAC version?

DAC stands for Drug Affinity Complex, a maleimide group that lets the CJC-1295 molecule bind covalently to albumin in the bloodstream. Once bound to albumin, the peptide is protected from enzymatic degradation, which is why CJC-1295 with DAC has a reported half-life of roughly 6 to 8 days in circulation, versus about 30 minutes for the unmodified peptide ^[7]. GHRP-6 has no DAC version. DAC is a modification specific to the CJC-1295/Mod GRF 1-29 family of GHRH analogues. If you see "GHRP-6 DAC" advertised anywhere, that's a red flag for a mislabeled or fabricated product, not a real pharmacological variant. This matters for dosing logic. CJC-1295 without DAC needs frequent dosing (often daily or even multiple times per day in research protocols) to maintain a pulsatile pattern that resembles natural GH release. CJC-1295 with DAC is dosed far less often, sometimes twice weekly, because it lingers in the blood and produces a sustained elevation in GH and IGF-1 rather than a sharp pulse ^[7]. GHRP-6, regardless of what it's paired with, is short-acting and typically dosed multiple times a day to hit GH pulses around meals or training. For a detailed breakdown of frequency and unit conversion, see cjc 1295 dosage and the cjc-1295 dac dosage calculator.

Why is GHRP-6 known for making people so hungry?

GHRP-6 activates GHS-R1a in the arcuate nucleus of the hypothalamus, the same brain region where endogenous ghrelin signals hunger. Human studies on ghrelin itself found that intravenous infusion markedly increased self-reported hunger and food intake at a subsequent buffet meal, with one trial reporting roughly a 28% increase in caloric intake compared to placebo ^[8]. GHRP-6 shares this mechanism closely enough that appetite stimulation is one of its most consistently reported effects in older clinical pharmacology literature on GHRPs, not a rare or idiosyncratic side effect. Some early research even proposed GHRP-6 analogues as potential treatments for cachexia and appetite loss in wasting conditions, precisely because the hunger effect was so reliable ^[3]. For someone trying to control body composition or manage a client's meal timing, this is a real practical decision point. GHRP-6 users often report needing to eat within 20 to 30 minutes of a dose or dealing with uncomfortable hunger pangs. CJC-1295 alone doesn't produce this. That's one reason people who want GH pulsing without the hunger switch gravitate toward GHRH analogues paired with a lower-appetite-effect GHRP like ipamorelin instead.

Why is CJC-1295 usually paired with ipamorelin instead of GHRP-6?

Ipamorelin is also a ghrelin-receptor agonist, in the same GHRP family as GHRP-6, but it was selected in development specifically for being more selective at GHS-R1a with less effect on cortisol, prolactin, and appetite compared to older GHRPs like GHRP-6 ^[9]. That selectivity is the whole reason it became the default pairing partner for CJC-1295 in research and off-label use. The combination logic is identical to CJC-1295 plus GHRP-6: a GHRH-receptor agonist plus a ghrelin-receptor agonist, aiming for a larger, more pulsatile GH release than either alone, based on the older combination pharmacology data described above ^[5]. What's different is the side-effect profile people report anecdotally, less hunger, less reported cortisol/prolactin bump with ipamorelin than with GHRP-6. It's worth being blunt here: there is no published randomized trial testing CJC-1295 plus ipamorelin, or CJC-1295 plus GHRP-6, as combination products in humans. The combined-GH data comes from studies of individual GHRH analogues and individual GHRPs, often different specific molecules, done decades ago in small groups, sometimes in patients with GH deficiency rather than healthy adults ^[5]. Anyone telling you the CJC-1295/ipamorelin stack is "clinically proven" as a combination is overstating what the literature actually shows. Read the mechanism and study history in more depth at cjc 1295 with dac.

Is there any human evidence for GHRP-6 specifically?

Yes, though most of it is old and narrow. GHRP-6 was one of the first synthetic GH secretagogues studied in the late 1980s and 1990s, with published work characterizing its GH-releasing potency and its interaction with GHRH in both healthy volunteers and GH-deficient patients ^[3][5]. Those studies established the mechanism (ghrelin receptor agonism, somatostatin suppression) and confirmed dose-dependent GH release. What's missing is any modern trial evaluating GHRP-6 for body composition, athletic performance, anti-aging use, or long-term safety in healthy adults, the actual reasons most people buy it today. The historical literature was aimed at understanding GH axis physiology and potential treatment of GH deficiency or wasting syndromes, not at the use cases driving current demand. CJC-1295 has a comparable gap. The core pharmacokinetic study describing its extended half-life with DAC was conducted in a limited number of subjects and published in 2006 ^[7]. Neither peptide has the kind of large, multi-year safety and efficacy trial base that an FDA-approved GH secretagogue like tesamorelin has for its approved indication (HIV-associated lipodystrophy) .

What are the known and reported side effects of each?

CJC-1295's most commonly reported effects mirror general GH-axis stimulation: injection site redness, headache, flushing, and water retention, along with the theoretical concern of raising IGF-1 chronically with the DAC version, which sustains elevated hormone levels rather than a natural pulse-and-trough pattern ^[1][7]. Detailed side effect information is covered at cjc 1295 side effects. GHRP-6's most distinct additional effects, beyond the shared GH-axis effects, are the appetite surge already discussed and reported increases in cortisol and prolactin in some studies, a known characteristic of first-generation GHRPs compared to newer, more receptor-selective options ^[3][9]. Water retention and mild insulin resistance from elevated GH are also reported concerns with any GH secretagogue used at higher doses or for extended periods, since GH itself antagonizes insulin action. Because neither peptide is FDA-approved, there is no formal post-market adverse event surveillance system tracking them the way there is for approved drugs. Reported side effects come from small clinical pharmacology trials, case reports, or user self-report, not large-scale monitoring.

How do dosing protocols actually differ in practice?

CJC-1295 without DAC is typically discussed in research and forum protocols at low microgram doses (often in the range of 100 mcg per administration) given once or multiple times daily, timed around sleep or fasted states to approximate a natural GH pulse. CJC-1295 with DAC, because of its multi-day half-life, is dosed far less frequently, often twice weekly, at doses in a similar or somewhat higher microgram range, since it's meant to create a sustained elevation rather than a sharp spike ^[7]. GHRP-6 protocols described in older clinical literature and current informal use both favor short-acting, multiple-times-daily dosing (commonly around 1-3 times per day) timed away from meals given its strong appetite effect, since taking it right before eating undercuts any body-composition goal and taking it right after eating can blunt the GH pulse (a high-glucose or high-fat state can suppress GHRP-triggered GH release). Neither peptide has an FDA-approved dosing label. Every number cited here comes from published pharmacokinetic studies in small cohorts or from accumulated informal protocols, not a package insert. Anyone using either compound should treat these ranges as starting points from the literature, not prescriptions. Full unit conversion and reconstitution math is in cjc 1295 dosage.

Which one is better for fat loss, muscle gain, or sleep?

There's no head-to-head human trial comparing CJC-1295 against GHRP-6 for fat loss, muscle gain, or sleep quality. Any claim that one is "better" for a specific goal is extrapolation from mechanism, not outcome data. What can be said honestly: GH itself, when chronically elevated, has lipolytic (fat-mobilizing) effects and can support lean mass indirectly through IGF-1 signaling, and this is the physiological basis both peptides are trying to exploit by raising endogenous GH ^[1][7]. GHRP-6's appetite stimulation is a practical liability for fat loss goals specifically, since it makes calorie restriction harder to sustain, an issue CJC-1295 doesn't share and that ipamorelin shares to a much lesser degree than GHRP-6 ^[9]. For sleep, GH release naturally peaks during slow-wave sleep, and secretagogues dosed at bedtime are often chosen to align with and amplify that natural pulse, a rationale that applies to any short-acting GH secretagogue, not something unique to either molecule.

Can CJC-1295 and GHRP-6 be used together safely?

Mechanistically, yes, they act on different receptors and the combination logic (GHRH agonist plus ghrelin-receptor agonist producing a larger pulse than either alone) has real support from older combination pharmacology studies ^[5]. Practically and from a safety-evidence standpoint, no controlled human trial has tested the specific combination of CJC-1295 and GHRP-6 for safety, dosing, or outcomes. That gap matters more than it sounds. Two compounds each having some human data doesn't mean their combination has been shown safe at any particular dose or duration. It means the individual mechanisms are understood reasonably well and the combination is a reasonable hypothesis, not a validated protocol. Anyone considering combination use should also factor in that neither peptide is manufactured under FDA-approved quality standards for human use, so sourcing and purity control matters as much as the pharmacology. See cjc 1295 for sale for how to think about that side of it, and always confirm product identity through third-party testing rather than seller claims alone.

CJC-1295 vs GHRP-6 vs ipamorelin: quick comparison

Where CJC-1295 Co fits into this

CJC-1295 Co doesn't compound or manufacture any peptide. The site exists to explain the mechanism, dosing math, and evidence base clearly, and to point readers toward a provider-reviewed pathway with pharmacy fulfillment, so that anyone who decides to move forward does it through a channel with clinical oversight and quality control rather than an anonymous research-chemical vendor. If you're comparing CJC-1295 protocols before deciding anything, the dosage and DAC breakdowns linked throughout this article are the right next stop.

Frequently asked questions

Is CJC-1295 stronger than GHRP-6 for raising GH?

They're not directly comparable in "strength" because they work through different receptors and different mechanisms. CJC-1295 extends and amplifies a GH pulse via GHRH receptor activation; GHRP-6 triggers a pulse via the ghrelin receptor and suppresses somatostatin. Combination studies of GHRH analogues with GHRPs found a greater-than-additive effect than either alone, but no trial ranks CJC-1295 against GHRP-6 head to head ^[5].

Does GHRP-6 have a DAC version like CJC-1295?

No. DAC (Drug Affinity Complex) is a chemical modification specific to CJC-1295 that lets it bind albumin and extend its half-life to roughly 6-8 days ^[7]. GHRP-6 has no equivalent DAC formulation; any product labeled that way should be treated as suspect.

Why does GHRP-6 make you so hungry?

GHRP-6 activates the ghrelin receptor (GHS-R1a) in the hypothalamus, the same receptor the natural hunger hormone ghrelin uses. Human ghrelin infusion studies show marked increases in hunger and food intake, sometimes around 28% more calories eaten at a test meal versus placebo, and GHRP-6 shares this mechanism ^[8].

Can I use CJC-1295 without GHRP-6 or ipamorelin?

Yes. CJC-1295 alone will amplify GH pulses through the GHRH receptor without triggering the ghrelin-receptor effects (appetite, somatostatin suppression) that a GHRP adds. Many protocols use CJC-1295 alone, though combining it with a GHRP is common because the two mechanisms are additive or greater than additive in older pharmacology studies ^[5].

Is CJC-1295 or GHRP-6 FDA-approved?

Neither is FDA-approved for any indication. Both are sold as research chemicals, and FDA guidance on nominated bulk substances has found peptides in this category do not qualify for pharmacy compounding under sections 503A or 503B of the FD&C Act ^[4].

What's the difference between GHRP-6 and GHRP-2?

Both are ghrelin-receptor agonists from the same peptide family studied since the late 1980s. GHRP-6 is more strongly associated with appetite stimulation, while GHRP-2 is generally reported as a more potent GH secretagogue with a somewhat smaller hunger effect, though direct comparative human data is limited ^[3].

How often do you inject CJC-1295 versus GHRP-6?

CJC-1295 without DAC needs frequent dosing (often daily) because its half-life is about 30 minutes; with DAC, twice-weekly dosing is common due to its multi-day half-life ^[6][7]. GHRP-6, being short-acting, is typically dosed multiple times daily, timed away from meals.

Does CJC-1295 cause water retention?

Water retention is a commonly reported effect of GH-axis stimulation generally, including with CJC-1295, especially the DAC version that sustains elevated GH and IGF-1 levels rather than producing a pulse-and-trough pattern ^[1][7]. It's considered dose and duration dependent, though no large controlled trial has quantified incidence precisely.

Is there a clinical trial comparing CJC-1295 and GHRP-6 directly?

No published randomized controlled trial compares the two compounds head to head, and none tests the combination of CJC-1295 plus GHRP-6 specifically. Existing combined-GH data comes from older studies pairing different individual GHRH analogues with different individual GHRPs ^[5].

Which is safer, CJC-1295 or GHRP-6?

Neither has a large modern safety database. GHRP-6 has more consistently reported effects on cortisol, prolactin, and appetite in older literature compared to newer GHRPs like ipamorelin ^[3][9]. CJC-1295's main theoretical concern, especially with DAC, is sustained rather than pulsatile GH/IGF-1 elevation. Both need to be judged against the fact that neither is FDA-approved or monitored via formal adverse event reporting.

Why is ipamorelin more popular than GHRP-6 today?

Ipamorelin was developed specifically to be more selective at the ghrelin receptor, with less reported effect on cortisol, prolactin, and appetite than GHRP-6, which is why it became the default GHRP pairing partner for CJC-1295 in current use, despite sharing the same basic mechanism ^[9].

Does GHRP-6 raise cortisol and prolactin?

Older clinical pharmacology studies of GHRP-6 and related first-generation GHRPs reported increases in cortisol and prolactin alongside GH release, a characteristic that later, more receptor-selective GHRPs like ipamorelin were specifically designed to minimize ^[3][9].

Sources

1. National Center for Biotechnology Information, PubChem: CJC-1295 compound summary: CJC-1295 is a synthetic GHRH analogue derived from the first 29 amino acids of native GHRH
2. NCBI PubChem: GHRP-6 compound summary: GHRP-6 is a synthetic hexapeptide that acts as a ghrelin receptor (GHS-R1a) agonist
3. Bowers CY, 'Growth hormone-releasing peptide (GHRP)', Cellular and Molecular Life Sciences, 1998: GHRP-6 and related GHRPs stimulate GH release via a distinct receptor and were studied historically for conditions involving appetite loss, with reported cortisol and prolactin effects
4. Bowers CY et al., 'On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone', Endocrinology, 1984: Combining a GHRH analogue with a GHRP produces a greater-than-additive GH release compared to either compound alone
5. NCBI PubChem: Sermorelin/GHRH(1-29) pharmacokinetics summary: Unmodified GHRH(1-29) analogues have a short circulating half-life of roughly 30 minutes
6. Teichman SL et al., 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting growth-hormone-releasing hormone analog', Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 with DAC has an extended half-life of approximately 6 to 8 days and produces sustained elevation of GH and IGF-1
7. Wren AM et al., 'Ghrelin enhances appetite and increases food intake in humans', Journal of Clinical Endocrinology & Metabolism, 2001: Intravenous ghrelin infusion increases hunger and food intake in humans, by roughly 28% in caloric intake in the study's test meal
8. Raun K et al., 'Ipamorelin, the first selective growth hormone secretagogue', European Journal of Endocrinology, 1998: Ipamorelin was developed as a selective ghrelin receptor agonist with minimal effect on cortisol, prolactin, and appetite compared to earlier GHRPs
9. U.S. Food and Drug Administration, Egrifta (tesamorelin) approval and label: Tesamorelin is an FDA-approved GHRH analogue with a specific approved indication (HIV-associated lipodystrophy), unlike CJC-1295 or GHRP-6